The Engineer Who Reads Disease Like a Circuit Board
Somewhere inside the human body, a protein called Protein S quietly moderates the blood's ability to clot. For decades, it was an overlooked character in a crowded cast of hemostasis players. Almost nobody was developing drugs against it. Adam Rosenthal noticed. He built a company around it, raised $315 million, and is now running a Phase 3 trial with an antibody that could replace the current standard of care for an entire category of bleeding disorders - one monthly subcutaneous injection in place of two or three weekly IV infusions.
That is the rhythm of how Rosenthal works. He looks where others don't. He trained as an electrical engineer at MIT, earned a second bachelor's in Brain and Cognitive Science, stacked a master's degree in electrical engineering and computer science on top of that, and then completed a PhD in Biomedical Engineering jointly at MIT and Harvard. Five degrees. The range wasn't academic indulgence - it built an unusually wide pattern-recognition lens. When he arrived in biotech, he brought the systems-thinking of an engineer into biology's messy, probabilistic world.
The Career That Prepared Him
Before founding Star, Rosenthal spent years inside other people's companies learning the mechanics of the game. At Boston Consulting Group, he was a project leader - the consultant's version of operations training. From there, he moved to iPierian as Vice President, Head of Corporate Development. iPierian was eventually acquired by Bristol-Myers Squibb for $725 million.
Next came True North Therapeutics, where Rosenthal served as Chief Business Officer. He raised more than $140 million in private financing and helped navigate the company to a $825 million acquisition by Bioverativ. Two exits, combined value: $1.55 billion. Each chapter taught him something the next one required. He understood how deals close, how capital moves, and how rare disease programs get killed not by bad science but by bad portfolio prioritization inside large organizations.
That observation became the founding logic of Star.
A Company Built Like a Solar System
Rosenthal launched Star Therapeutics in 2018 with a model most biotech founders don't attempt: a hub-and-spoke structure in which Star serves as a central research engine, spinning out independent companies around each validated biological program. The first spinout was Electra Therapeutics, focused on immunology and immuno-oncology. The second was Vega Therapeutics, targeting rare hematologic diseases. Each subsidiary operates with its own focus, its own capital stack, and its own freedom to explore the biology without being sacrificed to another program's milestone needs.
The insight behind this design is precise. Inside traditional biotechs, portfolio companies face forced prioritization decisions. Program A might have better short-term data, so Program B gets shelved, even if Program B is addressing a disease with no alternatives. Rosenthal's answer: give each program its own house. "Putting them in their own company that's entirely focused on that area of biology allows you to fully explore the potential," he has explained.
Star operated in stealth from 2018 to 2022 - four years of building before anyone outside the investor circle knew it existed. When it emerged in February 2022, it had already raised over $100 million and had two clinical-stage spinouts in motion.
The Biology First Principle
Rosenthal's scientific philosophy inverts the conventional drug development approach. Most programs start with a target and hunt for a disease it might address. Star starts with constellations of diseases - mapping the pathobiology across them to find shared mechanisms. "We take a unique approach and start by exploring constellations of numerous diseases and looking for common pathobiology across them," he said in an interview with Inside Precision Medicine. "With this strategy, we follow the biology to uncover key pathways that open up multiple potential opportunities."
The implication is portfolio resilience. "Even if the drug candidate or pathway turns out to not be optimal for disease A," Rosenthal has noted, "it could very well be optimal for diseases B and C." A failed indication isn't a failed program - it's a rerouted one. This logic made Star attractive to investors even before it had clinical data, because the model itself reduced single-point-of-failure risk.
VGA039: The Drug That Defines the Era
Star's lead asset is VGA039, a first-in-class monoclonal antibody targeting Protein S. Von Willebrand disease - the most common inherited bleeding disorder, affecting more than 50,000 diagnosed and treated patients in the US - has long been a disease without a good answer. Current treatments for the most severe patients require IV infusions two to three times per week. The treatment burden is significant. Patients frequently undertreat themselves or avoid certain activities to minimize bleeding risk.
VGA039 works differently. By targeting Protein S, it restores balance in the blood coagulation process - generating thrombin in a way that compensates for the deficient von Willebrand factor. In interim Phase 1/2 multidose data presented at the ASH Annual Meeting in December 2024, VGA039 administered subcutaneously once monthly produced substantial reductions in annual bleeding rate across all types of VWD and all types of bleeds. Every patient in the trial responded.
In January 2025, the FDA granted VGA039 Fast Track Designation. By September 2025, Star had closed an oversubscribed $125 million Series D - co-led by Sanofi Ventures and Viking Global Investors, with participation from Janus Henderson, Frazier Life Sciences, and 14 other investors - and initiated its Phase 3 VIVID-6 trial. The study is targeting roughly 60 patients across all VWD types, with results expected around 2028.
"We're still in generation 1.0 and we're hoping to leapfrog all that incremental innovation and go straight to a subcutaneous therapy," Rosenthal has said. He frames VGA039's potential with characteristic directness: "It's one of those rare circumstances where the market potential is so big, but the spend to get to market is actually quite small. It's something that an independent biotech can very easily do on their own."
What He Is Building Next
Star's ambitions extend beyond VWD. The company is exploring VGA039's potential in other blood disorders. The hub model was always designed to scale - not just to one clinical win but to a family of programs pursuing shared biology across rare diseases. Rosenthal has kept options open on commercialization: independent development, a partnership, or an eventual IPO. The move depends on what serves patients best at each stage.
With $315 million raised, a Phase 3 underway, and two prior exits totaling $1.55 billion, Adam Rosenthal is playing a longer game than most founders attempt. He built a company designed to think across disease boundaries - and it is now at the stage where the science either validates the theory or doesn't.
The biology, so far, is cooperating.